Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027001 | 0.88 | IDO1 (0.55) | MAP4K4IDO1CCNCCDK8RECQL | |
| SCHEMBL25070215 | 0.84 | ADORA2A (0.54) | IDO1CCNCCDK8CYP1A2CNR1 | |
| SCHEMBL4672168 | 0.84 | LMNA (0.52) | IDO1CCNCCDK8RECQLLOX | |
| SCHEMBL4932513 | 0.83 | MAPK14 (0.52) | MAP4K4IDO1CCNCCDK8RECQL | |
| SCHEMBL28163101 | 0.83 | CCNC (0.46) | MAP4K4IDO1CCNCCDK8RECQL | |
| SCHEMBL14770762 | 0.83 | IDO1 (0.44) | IDO1CCNCCDK8RECQLLOX | |
| SCHEMBL12050763 | 0.83 | ESR2 (0.47) | IDO1ALOX5CCNCCDK8RECQL | |
| SCHEMBL29461217 | 0.82 | ADORA2A (0.56) | IDO1CCNCCDK8CYP1A2RECQL | |
| SCHEMBL2329610 | 0.82 | ADORA2A (0.56) | IDO1CCNCCDK8CYP1A2RECQL | |
| SCHEMBL16242324 | 0.82 | MAP4K4 (0.62) | MAP4K4ALOX5AHRCYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1659112-B1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET SOC CIV (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1659112-B1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET SOC CIV (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1659112-A1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET (FR) | 2006-05-24 | — | — | EP | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | MAP4K4 2372/4885IDO1 4261/4885ALOX5 3405/4885 |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | DRD2, HTR2C, DRD3 | MAP4K4 1599/4885IDO1 1529/4885ALOX5 2065/4885 |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | CYP4Z1, CYP3A5, CYP1A2 | MAP4K4 322/4885IDO1 320/4885ALOX5 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.